1. Home
  2. KPTI vs CODA Comparison

KPTI vs CODA Comparison

Compare KPTI & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • CODA
  • Stock Information
  • Founded
  • KPTI 2008
  • CODA 1994
  • Country
  • KPTI United States
  • CODA United States
  • Employees
  • KPTI N/A
  • CODA N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • CODA Industrial Machinery/Components
  • Sector
  • KPTI Health Care
  • CODA Industrials
  • Exchange
  • KPTI Nasdaq
  • CODA Nasdaq
  • Market Cap
  • KPTI 81.1M
  • CODA 92.5M
  • IPO Year
  • KPTI 2013
  • CODA N/A
  • Fundamental
  • Price
  • KPTI $0.63
  • CODA $7.82
  • Analyst Decision
  • KPTI Strong Buy
  • CODA Strong Buy
  • Analyst Count
  • KPTI 4
  • CODA 1
  • Target Price
  • KPTI $5.00
  • CODA $11.00
  • AVG Volume (30 Days)
  • KPTI 678.9K
  • CODA 34.0K
  • Earning Date
  • KPTI 02-27-2025
  • CODA 03-17-2025
  • Dividend Yield
  • KPTI N/A
  • CODA N/A
  • EPS Growth
  • KPTI N/A
  • CODA 14.29
  • EPS
  • KPTI N/A
  • CODA 0.32
  • Revenue
  • KPTI $148,442,000.00
  • CODA $20,316,161.00
  • Revenue This Year
  • KPTI $5.47
  • CODA $22.31
  • Revenue Next Year
  • KPTI $6.33
  • CODA $12.02
  • P/E Ratio
  • KPTI N/A
  • CODA $24.53
  • Revenue Growth
  • KPTI 1.77
  • CODA 4.98
  • 52 Week Low
  • KPTI $0.58
  • CODA $5.48
  • 52 Week High
  • KPTI $1.70
  • CODA $9.89
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • CODA 41.62
  • Support Level
  • KPTI $0.60
  • CODA $7.75
  • Resistance Level
  • KPTI $0.70
  • CODA $8.13
  • Average True Range (ATR)
  • KPTI 0.05
  • CODA 0.34
  • MACD
  • KPTI -0.00
  • CODA -0.05
  • Stochastic Oscillator
  • KPTI 46.61
  • CODA 7.22

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About CODA Coda Octopus Group Inc. Common stock

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. It operates in two segments: Marine Technology Business and Marine Engineering Business. The Technology Business develops proprietary solutions for both the commercial and defense subsea market. Its solutions include hardware and software for Geophysical Systems, Motion & Positioning Systems, and Real-Time Volumetric Imaging Sonar. The Engineering Business segment provides engineering services to a range of clients in the defense markets. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Marine Technology Business segment.

Share on Social Networks: